Search
Citas y referencias (22)
Invitrogen™
FluoReporter™ lacZ/Galactosidase Quantitation Kit
El kit de cuantificación de lac Z/Galactosidasa FluoReporter™ incluye el sustrato β-galactosidasa, 3-carboxiumbeliferil β-D-galactopiranósido que genera el producto de hidrólisisMás información
| Número de catálogo | Cantidad |
|---|---|
| F2905 | 1 kit |
Número de catálogo F2905
Precio (CLP)
395.181
Each
Cantidad:
1 kit
Precio (CLP)
395.181
Each
El kit de cuantificación de lac Z/Galactosidasa FluoReporter™ incluye el sustrato β-galactosidasa, 3-carboxiumbeliferil β-D-galactopiranósido que genera el producto de hidrólisis fluorescente-azul, ácido 7-hidroxicumarina-3-carboxílico.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
ensayoEnsayo de β-Gal (lacZ)
Método de detecciónFluorescente
Línea de productosFluoReporter
Tipo de productoSistema de ensayo de gen indicador de β-galactosidasa
Cantidad1 kit
Condiciones de envíoTemperatura ambiente
SustratoCUG
Propiedades de sustratoSustrato químico
Tipo de sustratoSustrato Beta-Gal
Enzima dianaBeta-galactosidasa
FormatoKit
Unit SizeEach
Contenido y almacenamiento
Almacenar en el congelador (de -5 a -30 °C) y proteger de la luz.
Citations & References (22)
Citations & References
Abstract
Substrate-labeled fluorescent immunoassay for phenobarbital.
Journal:Ther Drug Monit
PubMed ID:7013165
An assay for the anticonvulsant drug phenobarbital (PB) has been developed that is based on the principles of the substrate-labeled fluorescent immunoassay. A fluorogenic enzyme substrate, galactosyl umbelliferone, was covalently linked to a derivative of PB. The labeled drug, galactosyl umbelliferone-PB (GUPB), is nonfluorescent under conditions of the assay; however,
Substrate-labeled fluorescent immunoassay for measuring dibekacin concentrations in serum and plasma.
Journal:Antimicrob Agents Chemother
PubMed ID:6357071
'We have developed a homogeneous substrate-labeled fluorescent immunoassay for the measurement of dibekacin concentrations in serum and plasma. The fluorogenic enzyme substrate beta-galactosyl-umbelliferone was covalently attached to tobramycin, an aminoglycoside structurally similar to dibekacin, to prepare a fluorogenic drug reagent (FDR). The FDR is nonfluorescent under assay conditions, but fluoresces
A homogeneous fluorescent immunoassay for human immunoglobulin M.
Journal:Clin Chem
PubMed ID:7014030
'We describe a homogeneous substrate-labeled fluorescent immunoassay for human IgM. In this competitive-binding method we use a fluorogenic substrate for Escherichia coli beta-galactosidase, N-(6-aminohexyl)-7-beta-galactosyl-coumarin-3-carboxamide, which is covalently coupled to IgM. The fluorescence emission intensity of the labeled IgM at 450 nm (with excitation at 400 nm) is negligible, but when
Substrate-labeled fluorescent immunoassay for phenytoin in human serum.
Journal:Clin Chem
PubMed ID:108033
'A homogeneous substrate-labeled fluorescent immunoassay has been applied to the measurement of phenytoin concentrations in human serum. We coupled a fluorogenic enzyme substrate, galactosyl-umbelliferone, covalently to a derivative of phenytoin. Under assay conditions, this drug-substrate conjugate was nonfluorescent but became fluorescent upon hydrolysis catalyzed by bacterial beta-galactosidase. When antibody to
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2.
Journal:J Virol
PubMed ID:12388712
'We examined cytoplasmic trafficking and nuclear translocation of adeno-associated virus type 2 (AAV) by using Alexa Fluor 488-conjugated wild-type AAV, A20 monoclonal antibody immunocytochemistry, and subcellular fractionation techniques followed by DNA hybridization. Our results indicated that in the absence of adenovirus (Ad), AAV enters the cell rapidly and escapes from